D1 vs D2 Lymphadenectomy in Gastric Cancer
Launched by FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL CLÍNICO DE VALENCIA · Feb 22, 2022
Trial Information
Current as of May 19, 2025
Completed
Keywords
ClinConnect Summary
In this propensity score-matched analysis of 128 patients, D2 lymphadenectomy improved long-term outcomes compared with D1 in patients with curative intent surgery for gastric cancer except for the group of patients older than 75 years and with early tumors.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients diagnosed with GC stage I-III who underwent a curative gastrectomy +/- perioperative chemotherapy
- Exclusion Criteria:
- • patients with adenocarcinoma Siewert type I/II, palliative surgery, R1/R2 resections and pathological stage (pStage) IV.
About Fundación Para La Investigación Del Hospital Clínico De Valencia
The Fundación para la Investigación del Hospital Clínico de Valencia is a prominent research organization dedicated to advancing medical knowledge and improving patient care through clinical trials and biomedical research. Based in Valencia, Spain, the foundation collaborates closely with the Hospital Clínico Universitario de Valencia to facilitate innovative studies across various medical disciplines. Its mission is to promote scientific excellence and foster collaboration among healthcare professionals, researchers, and institutions, ultimately aiming to translate research findings into effective therapies and interventions for the benefit of patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials